This paper examines the effects of methamphetamine on the central nervous system through a review of recent neuroscientific research. The analysis covers methamphetamine-induced changes in the neocortex and parietal regions, impairment of the blood-brain barrier, short- and long-term effects on fetal brain development, microstructural white matter abnormalities, disruption of the acetylcholine system, increased gray matter volume, and enhanced locomotor activity. Drawing on studies of both animal models and human subjects in abstinence, the paper demonstrates that chronic methamphetamine abuse causes significant regional cerebral dysfunction and cognitive disturbances. The evidence indicates that methamphetamine represents a serious threat to neurological health across developmental stages and age groups.
Methamphetamine is a powerful stimulant that affects the central nervous system and is classified as a "hard" drug because of its potency and high addiction liability. Physically, methamphetamine appears as a white, odorless powder with a bitter taste and dissolves easily in liquids. It is highly addictive and difficult to discontinue. Common street names for the drug include meth, ice, crystal, and chalk.
Methamphetamine was developed in the twentieth century as a derivative of amphetamine, its parent drug. Originally, it was used in bronchial inhalers and nasal decongestants to help clear the sinuses and ease breathing. Beyond these therapeutic effects, methamphetamine produces euphoria and suppresses appetite. Critically, methamphetamine is significantly more potent and has longer-lasting and more harmful effects than amphetamine. For example, while amphetamine can be administered orally under medical supervision, methamphetamine cannot be safely given this way due to its extreme abuse potential. The drug produces an immediate but short-lived high, driving users to repeatedly administer it in search of the initial euphoric experience. This pattern of use makes methamphetamine far more prone to abuse than its parent compound. As a result, methamphetamine is illegal except when prescribed by a physician.
Given the widespread use of methamphetamine in the general population, understanding its effects on the brain is essential. This review examines how methamphetamine causes changes in the neocortex and parietal regions of the brain; how it affects short-term and long-term development of the fetal brain; how it produces microstructural abnormalities in white matter responsible for connecting the prefrontal cortex and hippocampus; how it disrupts the acetylcholine system; and how it increases gray matter volume and locomotor activity. Berman, Hassid, Isaacson, Ling, London, Mandelkern, Miotto, Monterosso, and Voytek (2008) demonstrated that individuals with a history of methamphetamine abuse exhibit mood and cognitive disturbances during periods of abstinence, reflecting regional cerebral dysfunction. This finding is alarming because it indicates that methamphetamine causes measurable brain damage in chronic users. The goal of this paper is to examine the neurobiological effects of methamphetamine on the brain and to increase awareness of its dangers.
Methamphetamine is a potent stimulant that produces euphoria and carries high abuse potential. Research has shown that methamphetamine causes significant disturbances in brain function. In a study of male mice, methamphetamine treatment impaired the blood-brain barrier (BBB), a critical structure that protects the brain from harmful substances. Mice were injected with seven different dosages of methamphetamine, ranging from 1.5 mg to 10 mg. To evaluate changes in BBB integrity, researchers used a fluorescent tracer. The results revealed a sevenfold increase in BBB permeability following methamphetamine exposure (Couraud et al., 2009). This breakdown of the protective barrier represents a serious threat to neural tissue and may contribute to the broader neurotoxic effects observed with chronic use.
Chronic methamphetamine abuse has been associated with measurable changes in the neocortex and parietal regions of the brain. Berman et al. (2008) investigated whether methamphetamine altered cerebral glucose metabolism during abstinence. The study compared ten methamphetamine-dependent individuals with twelve healthy control subjects. Researchers used positron emission tomography to measure cerebral glucose metabolism during methamphetamine abstinence. Methamphetamine-dependent subjects were tested 5 to 9 days after ceasing use and again 4 weeks later. Although glucose metabolism showed no significant changes, the researchers observed subtle structural changes in the neocortex and parietal regions, including loss of calbindin interneurons. These findings suggest that methamphetamine causes lasting neuronal damage even when acute metabolic effects are not detected.
In addition to changes in mature brain regions, methamphetamine produces both short-term and long-term effects on brain development, raising particular concerns for pregnant women and women of childbearing age who use the drug. To assess methamphetamine's developmental impact, Acevedo, Meer, Pfankuch, and Raber (2008) examined the effects of methamphetamine on neonatal mice. The researchers administered daily intraperitoneal injections of methamphetamine to newborn mice. They found that methamphetamine elevated histamine levels in the brain and activated the hypothalamic-pituitary-adrenal axis. Methamphetamine exposure also reduced levels of microtubule-associated protein 2, a dendritic marker in the hippocampus. This reduction in dendritic protein suggests that methamphetamine may impair long-term memory formation. Notably, female neonatal mice were more susceptible to these harmful changes than males, indicating sex-dependent vulnerability during critical developmental windows.
Methamphetamine has been shown to produce microstructural abnormalities in white matter, particularly in the pathways connecting the prefrontal cortex and the hippocampus. Bartzokis et al. (2009) conducted a study to evaluate whether methamphetamine abuse causes such microstructural damage. Twenty-three methamphetamine-dependent subjects underwent testing using fractional anisotropy imaging, which visualizes white matter structure in the prefrontal cortex at four different anatomical levels. Subjects were scanned on days 7, 13, and 18 of treatment retention. The study revealed that methamphetamine produced microstructural abnormalities in white matter, and these effects were present during the early weeks of abstinence. Notably, psychiatric symptoms emerged during this same abstinent period, suggesting a relationship between white matter integrity and behavioral or mood disturbances.
It has been documented that methamphetamine affects the acetylcholine system in the brain. Byung, Park, Raber, and Siegel (2011) assessed whether chronic methamphetamine abuse alters acetylcholine function. Three-month-old mice received daily injections of 5 mg of methamphetamine. Methamphetamine exposure increased the density of acetylcholine neurons in the basal forebrain and acetylcholine axons in the hippocampus. Importantly, methamphetamine did not affect gamma-aminobutyric acid (GABA) density or the total number of neurons in the basal forebrain, suggesting selective effects on cholinergic systems. The findings demonstrate that methamphetamine does affect the acetylcholine system, with stronger effects observed in females than in males.
"Age differences in methamphetamine-induced motor activity responses"
"Paradoxical gray matter expansion accompanying cognitive deterioration"
The studies reviewed here demonstrate that society is becoming increasingly equipped with knowledge about methamphetamine abuse and its neurobiological consequences. This growing understanding helps researchers and clinicians identify the diverse ways in which chronic methamphetamine use damages the brain. As awareness of the frightening consequences of methamphetamine use spreads, the community becomes better positioned to educate the public and discourage potential users from initiating use of this dangerous drug.
You’re 79% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.